None
Quote | Edesa Biotech Inc. (NYSE:EDSA)
Last: | $ |
---|---|
Change Percent: | -0.32% |
Open: | $3.1556 |
Close: | $3.16 |
High: | $3.23 |
Low: | $3.1338 |
Volume: | 23,044 |
Last Trade Date Time: | 02/12/2020 04:42:01 pm |
News | Edesa Biotech Inc. (NYSE:EDSA)
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
2024-05-10 16:34:57 ET More on Edesa Biotech Seeking Alpha’s Quant Rating on Edesa Biotech Historical earnings data for Edesa Biotech Financial information for Edesa Biotech Read the full article on Seeking Alpha For further details see: Ed...
Message Board Posts | Edesa Biotech Inc. (NYSE:EDSA)
Subject | By | Source | When |
---|---|---|---|
$EDSA: Hey, big THANKS to ya, Capt. S-L!!! | Invest-in-America | investorshub | 01/06/2023 1:51:37 AM |
Hey my brother I feel great that you | subslover | investorshub | 01/06/2023 1:04:59 AM |
$EDSA: Hey, & YOU'RE stock picks, Sir, have | Invest-in-America | investorshub | 01/04/2023 9:10:23 PM |
$2,26 close so that dip last week was | subslover | investorshub | 01/04/2023 9:02:12 PM |
Once the volume picks up, we will have | subslover | investorshub | 01/04/2023 6:57:00 PM |
News, Short Squeeze, Breakout and More Instantly...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...